Simulations Plus, Inc.

Researchers latest analysis from the AVERT-2 study (Assessing Very Early Rheumatoid Arthritis Treatment-2) investigates the relationship between serum exposure to subcutaneous (SC) abatacept and infection risk in adult patients with early RA. Curious about what this means for RA treatment and patient safety? Read more here: https://lnkd.in/gY5qNrAH

Will you be at the 14th??Annual Indiana CTSI Pharmacometrics Modeling and Simulation Symposium? We will! You won’t want to miss the presentation from Haiying Zhou, Executive Director, PBPK R&D at Simulations Plus—she’ll be speaking on March 19 about the application of PBPK modeling to support FIH predictions for non-small molecules. Details: https://lnkd.in/gMq2xVNh

Day 1 of MIDD+ Utrecht is in the books! Thank you to our presenters for sharing their insights and experience, as well as our attendees for participating in a day of learning and networking. We look forward to Day 2 tomorrow! If you'd like to hear about future in-person MIDD+ events, register for our email list: https://lnkd.in/grWuNb-5

If you’ll be at the SOT 64th Annual Meeting & ToxExpo, you won’t want to miss this presentation. Brunch & Learn: Recent Advances in Predicting Drug-Induced Liver Injury (DILI) by Chief Scientific Officer, Scott Siler, Ph.D. – Mar 19, 9:15-10:15 AM (Room W208C) ? ? And of course, be sure to stop by booth #1327 to say hello to our team!? https://lnkd.in/gmX-92fN

Understanding and predicting drug-drug interactions (DDIs) is crucial for ensuring patient safety and improving drug product development strategies. Not all pathways are created equally, however – the cytochrome P450 (CYP) enzyme family metabolizes the majority of marketed drugs, with many compounds also acting as perpetrators, making them a major source of clinically relevant DDIs. Join us this Thursday as Dr. Viera Lukacova and Dr. Xinyuan (Susie) Zhang outline a reliable, mechanistic PBPK modeling framework for predicting CYP enzyme-mediated DDIs with a high degree of confidence. You’ll learn practical strategies to identify, evaluate, and mitigate potential DDIs through modeling & simulation, ultimately ensuring drug product safety and supporting its regulatory approval. Register now to secure your spot. Register now! https://lnkd.in/gRCQGPG8

On International Women’s Day, we are proud to celebrate the impact of women scientists in the pharmaceutical industry. Their unwavering commitment to innovation and excellence propels scientific research and important treatments forward. We all benefit from the knowledge, creativity, and passion they bring to their work. Today, we honor their contributions and celebrate their impact. Thank you for your relentless pursuit of excellence and for making a difference every day! #InternationalWomensDay #WomenInScience #SimulationsPlus

Understanding and predicting drug-drug interactions (DDIs) is crucial for ensuring patient safety and improving drug product development strategies. Not all pathways are created equally, however – the cytochrome P450 (CYP) enzyme family metabolizes the majority of marketed drugs, with many compounds also acting as perpetrators, making them a major source of clinically relevant DDIs. Join Dr. Viera Lukacova (Chief Science Officer, PBPK/CHEM Solutions) and Dr. Xinyuan (Susie) Zhang (Vice President, Regulatory Strategies) for this webinar as they outline a reliable, mechanistic PBPK modeling framework for predicting CYP enzyme-mediated DDIs with a high degree of confidence. Specifically, this webinar will provide practical strategies to help you identify, evaluate, and mitigate potential DDIs through modeling & simulation, ultimately ensuring drug product safety and supporting its regulatory approval. What you will learn: 1. How to apply and interpret regulatory guidance and decision trees for evaluating CYP-mediated DDIs 2. The latest advancements using in vitro data and in silico tools for DDI prediction 3. Identification and integration of key clinical pharmacology information, including DDI data for more accurate risk assessment 4. The importance of high-quality DDI standard models and reports in providing validated, regulatory-aligned solutions Register now to secure your spot! https://lnkd.in/gRCQGPG8

If you missed out on conferences like AAPS PharmSci 360 last year, it doesn’t mean you have to miss out on the research presented. Scientist II Suvarchala kiranmai Avvari provided a recap of her poster, “Transporter-Mediated DDIs: Regulatory Guidance, PBPK Modeling” presented at AAPS 2024. Check out our other AAPS presentations here: https://lnkd.in/gD8cJUPi

The age of generative artificial intelligence (AI) is transforming scientific research and drug discovery—but many scientists are still trying to understand how they can harness it. This webinar, hosted by AAPS Science360 and presented by Priyata Kalra, Senior Scientist at Simulations Plus, will explore how AI and large language models (LLMs) are creating new opportunities for scientists to expand their impact and develop their career in synergy with these tools. Attendees will take away tips on evolving their process as the tools of genAI evolve, too. Register here: https://lnkd.in/gBcRUdqY

Congratulations to the winners of our ADMET Predictor? DILIsym? Module Outputs to Assess Liver Toxicity Rankings (On Demand workshop) giveaway: Bhargav Gunnepalli & Amol Walunjkar Please email [email protected] within the next 7 days for instructions on how to claim your free workshop!? Not the winner, but still want to learn? You can register to attend our workshops here: https://lnkd.in/gftu67c?